Cc-486: all 43 studies that test it

Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.Not yet recruitingNCT07463768Phase 2
• Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-InequalityRecruitingNCT06370000Phase 4
• Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid LeukemiaRecruitingNCT06022003Phase 2
• CC-486 and Venetoclax for Acute Myeloid LeukemiaRecruitingNCT05287568Phase 1
• Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaRecruitingNCT04803201Phase 2
• A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete RemissionActive, not recruitingNCT05197426Phase 2Results posted
• A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular LymphomaTerminatedNCT04722601Phase 1/2Results posted
• Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell MalignanciesCompletedNCT04447027Phase 1Results posted
• CC486-CHOP in Patients With Previously Untreated Peripheral T-cell LymphomaCompletedNCT03542266Phase 2Results posted
• Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian CancerTerminatedNCT02900560Phase 2Results posted
• Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT02546986Phase 2Results posted
• A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological DisordersCompletedNCT02494258Phase 2Results posted
• Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With FulvestrantTerminatedNCT02374099Phase 2Results posted
• Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal CarcinomaCompletedNCT02269943Phase 2Results posted
• Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung CancerCompletedNCT02250326Phase 2Results posted
• Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)CompletedNCT01845805Phase 2Results posted
• Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).CompletedNCT01835587Phase 1/2Results posted
• Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete RemissionCompletedNCT01757535Phase 3Results posted
• The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)CompletedNCT01566695Phase 3Results posted
• Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) PatientsWithdrawnNCT06180863Phase 2
• Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic SyndromesActive, not recruitingNCT05782127Phase 1/2
• A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)Active, not recruitingNCT05469737Phase 2/3
• An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete RemissionActive, not recruitingNCT05413018Phase 2
• A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid MalignanciesTerminatedNCT05209295Phase 1
• CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or RelapsedActive, not recruitingNCT05162976Phase 1
• Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic LeukemiaActive, not recruitingNCT05141682Phase 1/2
• Duvelisib in Combination With BMS-986345 in Lymphoid MalignancyCompletedNCT05065866Phase 1
• A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)CompletedNCT04887857Phase 1
• Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS PatientsCompletedNCT04806906Phase 2
• Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell LymphomaActive, not recruitingNCT04799275Phase 2/3
• Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell LymphomaWithdrawnNCT04639843Phase 1
• CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell LymphomaCompletedNCT04578600Phase 1
• A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With PlasmacytomaActive, not recruitingNCT04174196Phase 2
• Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCTCompletedNCT04173533Phase 3
• Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITLCompletedNCT03593018Phase 3
• Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486CompletedNCT03493646Phase 2
• Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT03450343Phase 1
• A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed LymphomaCompletedNCT02343536Phase 1
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
• Phase 1 Study of CC-486 in Japanese Subjects With Hematological NeoplasmsTerminatedNCT01908387Phase 1
• A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic SyndromesCompletedNCT01571648Phase 1
• Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung CancerCompletedNCT01545947Phase 1
• Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral AzacitidineCompletedNCT01519011Phase 1

← Cc-486 overview